多功能融合学习用于使用静止状态EEG信号预测阿尔茨海默病
Yonglin Chen1,2, Huabin Wang1,2, Dailei Zhang1
1Anhui Provincial Key Laboratory of Multimodal Cognitive Computation, Hefei, China.
Frontiers in neuroscience
|October 12, 2023
概括
这项研究引入了一种新的深度学习模型,用于使用电脑电图 (EEG) 信号预测阿尔茨海默病 (AD). 拟议的双分支网络实现了80.23%的准确性,在识别AD,FTD和正常控制方面表现优于现有的方法.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 使用脑电图 (EEG) 信号诊断阿尔茨海默病 (AD) 是一个挑战,因为复杂和杂的数据.
- 卷积神经网络 (CNN) 难以从EEG中提取有意义的损伤信号,而视觉转换器 (ViT) 在捕获全球模式方面表现出色.
研究的目的:
- 开发一种增强的深度学习方法,以改善AD风险评估.
- 利用CNN和ViT的互补优势,以更准确的基于EEG的AD预测.
主要方法:
- 提出了一个新的双分支特征融合网络 (DBN),集成CNN和ViT组件.
- 整合了空间注意力 (SA) 和频道注意力 (CA) 块,以增强特征歧视.
- 采用了双因素决策机制,结合了EEG信号一致性和迷你心理状态检查 (MMSE) 的分数.
主要成果:
- 在区分阿尔茨海默氏症,前性痴呆症 (FTD) 和正常控制 (NC) 试验对象方面,DBN实现了80.23%的分类准确性.
- 该方法与现有的基于EEG的最先进的AD预测技术相比,表现优越.
- 启用了在病理图像中突出区域的可视化,以便更好地解释AD预测.
结论:
- 拟议的混合CNN-ViT架构有效地从EEG信号中提取关键特征,用于AD预测.
- DBN模型在早期和准确诊断阿尔茨海默病方面提供了有前途的进展.
- 这种方法为AD评估中的EEG数据的临床解释和分析提供了宝贵的见解.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
11:01Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
13.7K
相关概念视频
Alzheimer's Disease: Overview
503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503
Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
